about
Tracking the 2015 Gastrointestinal Cancers Symposium: bridging cancer biology to clinical gastrointestinal oncologyElderly patients with advanced non-small cell lung cancer. A pase II study with weekly cisplatin and gemcitabine.High curative resection rate with weekly cisplatin, 5-fluorouracil, epidoxorubicin, 6S-leucovorin, glutathione, and filgastrim in patients with locally advanced, unresectable gastric cancer: a report from the Italian Group for the Study of DigestiveEpidermal Growth Factor Receptor (EGFR) gene copy number (GCN) correlates with clinical activity of irinotecan-cetuximab in K-RAS wild-type colorectal cancer: a fluorescence in situ (FISH) and chromogenic in situ hybridization (CISH) analysis.Natural history of malignant bone disease in hepatocellular carcinoma: final results of a multicenter bone metastasis survey.The role of LDH serum levels in predicting global outcome in HCC patients undergoing TACE: implications for clinical management.Trans-arterial chemo-embolization (TACE), with either lipiodol (traditional TACE) or drug-eluting microspheres (precision TACE, pTACE) in the treatment of hepatocellular carcinoma: efficacy and safety results from a large mono-institutional analysisCancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients.Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients.Clinical evidence for three distinct gastric cancer subtypes: time for a new approach.Prospective study of a molecular selection profile for RAS wild type colorectal cancer patients receiving irinotecan-cetuximabThe role of HER-3 expression in the prediction of clinical outcome for advanced colorectal cancer patients receiving irinotecan and cetuximab.Molecular biology of sporadic gastric cancer: prognostic indicators and novel therapeutic approaches.Pre-operative treatment modalities in gastric cancer patients.Phosphorylated AKT and MAPK expression in primary tumours and in corresponding metastases and clinical outcome in colorectal cancer patients receiving irinotecan-cetuximabAnti-EGFR strategies as an incremental step for the treatment of colorectal cancer patients: moving from scientific evidence to clinical practice.New target therapies in advanced pancreatic cancer.Epidermal growth factor receptor (EGFR) downstream signalling pathway in primary colorectal tumours and related metastatic sites: optimising EGFR-targeted treatment options.A combination of gefitinib and FOLFOX-4 as first-line treatment in advanced colorectal cancer patients. A GISCAD multicentre phase II study including a biological analysis of EGFR overexpression, amplification and NF-kB activation.Over-DI dissection may question the value of radiotherapy as a part of an adjuvant programme in high-risk radically resected gastric cancer patients.Pancreatic cancer: progress in cancer therapy.Women and lung cancer: clinical and molecular profiling as a determinate for treatment decisions: a literature review.Toward molecularly selected chemotherapy for advanced gastric cancer: state of the art and future perspectives.Multidisciplinary treatment of locally advanced rectal cancer: a literature review. Part 1.The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical managementEvolving strategies for the treatment of hepatocellular carcinoma: from clinical-guided to molecularly-tailored therapeutic options.5-Fluorouracil pharmacogenomics: still rocking after all these years?The Tower of Babel of liver metastases from colorectal cancer: are we ready for one language?Selected gastrointestinal cancer presentations from the American Society of Clinical Oncology annual meeting 2013 in review: it is not about the destination, it is about the journey.The challenge of targeted therapies for gastric cancer patients: the beginning of a long journey.The role of micro-RNAs in hepatocellular carcinoma: from molecular biology to treatment.The "angiogenetic ladder", step-wise angiogenesis inhibition in metastatic colorectal cancer.Pharmacogenomics of cetuximab in metastatic colorectal carcinoma.Recent aspects of sunitinib therapy in patients with metastatic clear-cell renal cell carcinoma: a systematic review of the literature.Metronomic chemotherapy from rationale to clinical studies: a dream or reality?The distinctive molecular, pathological and clinical characteristics of BRAF-mutant colorectal tumors.Role and mechanisms of resistance of epidermal growth factor receptor antagonists in the treatment of colorectal cancer.Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?The response of breast cancer cells to mesenchymal stem cells: a possible role of inflammation by breast implants.Neutrophil-to-lymphocyte ratio may be associated with the outcome in patients with prostate cancer.
P50
Q28085398-F2EBBEC5-4EC3-4C32-9E6B-17CE26063713Q33357939-28D8C2BD-052B-4087-938A-0994EFF7CBECQ33360403-38BB641E-4E95-4C5C-9A41-8F4498F05246Q33497634-95435BDB-AB65-48ED-9784-DD0083DBAD83Q34109952-1CD60AF2-A179-4DB5-BF2F-A0BD62D84207Q34213765-08D60B3D-2066-4B3C-AD67-7B856B3CB4FBQ34461553-293C47DC-E510-42C9-8578-7CDFD3A2C69DQ34984086-CFAF89DD-96AE-46F1-A69F-362175FDE687Q35034638-676E4FE2-CD00-4320-B1F9-BB704477F95FQ35050315-6A4D7795-400B-40A3-99E7-DA119BA4085BQ35583697-BE7E00D6-1983-438D-978C-37C4E0469C1FQ35584314-8352FA02-E9A0-468F-AC2C-89282DCD4319Q35832110-768945BD-9211-4880-93A4-F6A3401C9D7BQ36143651-98272173-C8FE-434B-94F7-218C52A3F4C4Q36207072-DFD2CEBF-A2AC-4F5D-A8AF-2501356713B7Q36425973-9A01E2D2-E6D3-48B7-8EBC-CB3A0121E3D8Q36522711-81097EE1-7B49-486D-9575-BA87FAE07DDDQ36608628-D3058CAA-1B92-4E74-9245-D2460E0E385AQ36608816-37E7471C-6517-43DA-85F0-0D92E9F4055EQ36616487-CF747293-B8CC-450F-9D41-E8F1CA1D5A00Q37115068-42C0D5DF-3FDD-415A-A7ED-F685A5C34D8CQ37250383-CD334217-990F-4379-B57A-7C2EC1588622Q37495094-A9F46702-9708-40DD-817E-9B6ED6AF8122Q37565629-3A52B911-54EA-4ADE-B2B9-05DE1DC28B73Q37595952-DD1552EC-B25E-491B-90E4-B85E180560DBQ37783666-4456DF97-9142-421D-8536-D232C10DF158Q37844550-3831BDB3-8AAA-4F10-B383-CA395F3F1EFAQ38042234-CEFD4E1B-6A30-4750-AACD-8752B52BE74DQ38166820-83FB9356-2601-437F-97BB-41D5352C054CQ38210070-83C13794-5707-4895-8CEF-E1EFF3D688C4Q38213933-27088B5F-AF49-4098-8656-E566797D5185Q38226586-B926C3A3-3414-4A7E-BE64-66B5E60D8E50Q38269777-70E53C6C-6766-4A4C-AE24-9E3616A9913CQ38334611-6AF98AD4-6910-4B29-8560-7E98D8B89F97Q38346010-DC75852D-C506-48B4-A8FA-F9497E2BF018Q38481038-F8AD5E46-D50A-4143-9197-A1BA32D34C5FQ38516244-720D096D-5FFA-4141-992C-369291CB05B0Q38554626-F38990B7-A5C3-41A1-8D78-55E61E60B941Q39053812-AA99D9A8-38EB-408A-9CC9-FC3182F3C1CAQ40824744-3C15C5EB-0682-488D-921D-0259A776B663
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mario Scartozzi
@ast
Mario Scartozzi
@en
Mario Scartozzi
@es
Mario Scartozzi
@nl
Mario Scartozzi
@sl
type
label
Mario Scartozzi
@ast
Mario Scartozzi
@en
Mario Scartozzi
@es
Mario Scartozzi
@nl
Mario Scartozzi
@sl
prefLabel
Mario Scartozzi
@ast
Mario Scartozzi
@en
Mario Scartozzi
@es
Mario Scartozzi
@nl
Mario Scartozzi
@sl
P106
P1153
6602818208
P21
P31
P496
0000-0001-5977-5546